Author

L. Schimanski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

K.-Y. A. Huang· 3 shared P. Rijal· 3 shared T. K. Tan· 3 shared A. Townsend· 2 shared C. Conceicao· 2 shared D. Bailey· 2 shared N. Thakur· 2 shared R. Harvey· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K.-Y. A. Huang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells

X. Zhuang, S. Tsukuda, F. Wrensch, P. A. Wing, M. Schilling, J. M. Harris, H. Borrmann, S. B. Morgan, J. L. Cane, L. Mailly, N. Thakur, C. Conceicao, H. Sanghani, L. Heydmann, C. Bach, , J. A. McKeating

This study shows BMAL1 regulates ACE2 expression and SARS-CoV-2 entry in lung epithelial cells, with SR9009 reducing viral replication through circadian mechanisms.

bioRxiv · Mar 20, 2021Microbiology

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

T. K. Tan, P. Rijal, R. Rahikainen, A. Keeble, L. Schimanski, S. Hussain, R. Harvey, J. Hayes, J. Edwards, R. McLean, V. Martini, M. Pedrera, N. Thakur, C. Conceicao, I. Dietrich, , R. Owens

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

bioRxiv · Aug 31, 2020Immunology

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans

K.-Y. A. Huang, T. Tan, T.-H. Chen, C.-G. Huang, R. Harvey, S. Hussain, C.-P. Chen, A. Harding, J. Gilbert-Jaramillo, X. Liu, M. Knight, L. Schimanski, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, , A. Townsend

This study analyzes plasmablast-derived antibodies in three COVID-19 patients, identifying neutralizing antibodies and cross-reactivity with other betacoronaviruses.

bioRxiv · Aug 28, 2020 · PreprintMicrobiology

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans

P. Rijal, B. B. Wang, T. K. Tan, L. Schimanski, P. Janesch, T. Dong, J. M. McCauley, R. S. Daniels, A. Townsend, K.-Y. A. Huang

This study identifies broadly reactive human monoclonal antibodies against N1 neuraminidase from vaccination and H7N9 infection, showing cross-inhibition of diverse N1 NAs and protective efficacy in mice.

bioRxiv · Jun 26, 2019Immunology